Skip to content
Fezolinetant
Veozah (fezolinetant) is a small molecule pharmaceutical. Fezolinetant was first approved as Veozah on 2023-05-12. The pharmaceutical is active against neuromedin-K receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Veozah
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fezolinetant
Tradename
Company
Number
Date
Products
VEOZAHAstellas PharmaN-216578 RX2023-05-12
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
veozahNew Drug Application2023-05-09
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Fezolinetant, Veozah, Astellas
94222992034-03-28DS, DPU-3622
99872742034-03-28U-3622
108367682034-03-28U-3621
88717612031-04-04DP
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hot flashesD019584—36——9
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MenopauseD008593EFO_0003922N95—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—6————6
Hepatic insufficiencyD0485501————1
Renal insufficiencyD051437HP_0000083N191————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFEZOLINETANT
INNfezolinetant
Description
Fezolinetant, sold under the brand name Veozah, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause. It is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which is under development by for the treatment of sex hormone-related disorders. It is developed by Astellas Pharma which acquired it from Ogeda (formerly Euroscreen) in April 2017.
Classification
Small molecule
Drug classtachykinin (neurokinin) receptor antagonists: NK3 receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1
Identifiers
PDB—
CAS-ID1629229-37-3
RxCUI—
ChEMBL IDCHEMBL3608680
ChEBI ID—
PubChem CID117604931
DrugBankDB15669
UNII ID83VNE45KXX (ChemIDplus, GSRS)
Target
Agency Approved
TACR3
TACR3
Organism
Homo sapiens
Gene name
TACR3
Gene synonyms
NK3R, TAC3R
NCBI Gene ID
6870
Protein name
neuromedin-K receptor
Protein synonyms
Neurokinin B receptor, neurokinin beta receptor, NK-3 receptor, NK-3R, NK3 receptor, Tachykinin receptor 3
Uniprot ID
Q0P510
Mouse ortholog
Tacr3 (21338)
neuromedin-K receptor (Q9JKN0)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 38 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details